- Zanubrutinib monotherapy for patients with treatment-naïve chronic lymphocytic leukemia and 17p deletion2021 | First Faculty of Medicine, Faculty of Medicine in Hradec Králové
- Zanubrutinib Versus Ibrutinib in Symptomatic Waldenström Macroglobulinemia: Final Analysis From the Randomized Phase III ASPEN Study2023 | Publication without faculty affiliation
- Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial2022 | First Faculty of Medicine, Faculty of Medicine in Hradec Králové
- Bruton's Tyrosine Kinase Inhibitor Zanubrutinib Effectively Modulates Cancer Resistance by Inhibiting Anthracycline Metabolism and Efflux2022 | Faculty of Pharmacy in Hradec Králové
- Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia2023 | Faculty of Medicine in Hradec Králové
- A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study2020 | First Faculty of Medicine, Faculty of Medicine in Hradec Králové
- Zanubrutinib for the treatment of MYD88 wild-type Waldenström macroglobulinemia: a substudy of the phase 3 ASPEN trial2020 | First Faculty of Medicine
- Zanubrutinib Versus Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: Interim Analysis of a Randomized Phase III Trial2023 | Faculty of Medicine in Hradec Králové
- Managing BTK inhibitor treatment-related adverse events in patients with chronic lymphocytic leukaemia - cardiovascular complications and bleeding2023 | First Faculty of Medicine, Faculty of Medicine in Hradec Králové